SGH
NBIX icon

Schonfeld Group Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Schonfeld Group Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$283K Buy
+5,000
New +$254K 0.18% 172

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Schonfeld Group Holdings's NBIX Position: Q4 2015 in Review

Schonfeld Group Holdings opened a new position in Neurocrine Biosciences (NBIX) in Q4 2015: 5,000 shares worth $283K. The stake represents 0.18% of the portfolio and ranks #172 among its holdings.

218 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Schonfeld Group Holdings held 5,000 shares of Neurocrine Biosciences worth $283K as of Q4 2015.
  • Neurocrine Biosciences was a new Schonfeld Group Holdings position in Q4 2015.
  • Neurocrine Biosciences made up 0.18% of Schonfeld Group Holdings's portfolio in Q4 2015, its #172 holding.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Schonfeld Group Holdings's 13F filing for Q4 2015, filed 12 Feb 2016.